Katherine A Epstein1, Catherine M Viscoli1, J David Spence1, Lawrence H Young1, Silvio E Inzucchi1, Mark Gorman1, Brett Gerstenhaber1, Peter D Guarino1, Anand Dixit1, Karen L Furie1, Walter N Kernan2. 1. From the Yale School of Medicine (K.A.E., C.M.V., L.H.Y., S.E.I., B.G., W.N.K.), New Haven, CT; University of Western Ontario (J.D.S.), London, Canada; Maine Medical Center (M.G.), Portland; Fred Hutchinson Cancer Research Center (P.D.G.), Seattle, WA; University of Newcastle Upon Tyne (A.D.), Newcastle, UK; and Alpert Medical School of Brown University (K.L.F.), Providence, RI. 2. From the Yale School of Medicine (K.A.E., C.M.V., L.H.Y., S.E.I., B.G., W.N.K.), New Haven, CT; University of Western Ontario (J.D.S.), London, Canada; Maine Medical Center (M.G.), Portland; Fred Hutchinson Cancer Research Center (P.D.G.), Seattle, WA; University of Newcastle Upon Tyne (A.D.), Newcastle, UK; and Alpert Medical School of Brown University (K.L.F.), Providence, RI. walter.kernan@yale.edu.
Abstract
OBJECTIVE: To assess whether smoking cessation after an ischemic stroke or TIA improves outcomes compared to continued smoking. METHODS: We conducted a prospective observational cohort study of 3,876 nondiabetic men and women enrolled in the Insulin Resistance Intervention After Stroke (IRIS) trial who were randomized topioglitazone or placebo within 180 days of a qualifying stroke or TIA and followed up for a median of 4.8 years. A tobacco use history was obtained at baseline and updated during annual interviews. The primary outcome, which was not prespecified in the IRIS protocol, was recurrent stroke, myocardial infarction (MI), or death. Cox regression models were used to assess the differences in stroke, MI, and death after 4.8 years, with correction for adjustment variables prespecified in the IRIS trial: age, sex, stroke (vs TIA) as index event, history of stroke, history of hypertension, history of coronary artery disease, and systolic and diastolic blood pressures. RESULTS: At the time of their index event, 1,072 (28%) patients were current smokers. By the time of randomization, 450 (42%) patients had quit smoking. Among quitters, the 5-year risk of stroke, MI, or death was 15.7% compared to 22.6% for patients who continued to smoke (adjusted hazard ratio 0.66, 95% confidence interval 0.48-0.90). CONCLUSION: Cessation of cigarette smoking after an ischemic stroke or TIA was associated with significant health benefits over 4.8 years in the IRIS trial cohort.
RCT Entities:
OBJECTIVE: To assess whether smoking cessation after an ischemic stroke or TIA improves outcomes compared to continued smoking. METHODS: We conducted a prospective observational cohort study of 3,876 nondiabetic men and women enrolled in the Insulin Resistance Intervention After Stroke (IRIS) trial who were randomized to pioglitazone or placebo within 180 days of a qualifying stroke or TIA and followed up for a median of 4.8 years. A tobacco use history was obtained at baseline and updated during annual interviews. The primary outcome, which was not prespecified in the IRIS protocol, was recurrent stroke, myocardial infarction (MI), or death. Cox regression models were used to assess the differences in stroke, MI, and death after 4.8 years, with correction for adjustment variables prespecified in the IRIS trial: age, sex, stroke (vs TIA) as index event, history of stroke, history of hypertension, history of coronary artery disease, and systolic and diastolic blood pressures. RESULTS: At the time of their index event, 1,072 (28%) patients were current smokers. By the time of randomization, 450 (42%) patients had quit smoking. Among quitters, the 5-year risk of stroke, MI, or death was 15.7% compared to 22.6% for patients who continued to smoke (adjusted hazard ratio 0.66, 95% confidence interval 0.48-0.90). CONCLUSION: Cessation of cigarette smoking after an ischemic stroke or TIA was associated with significant health benefits over 4.8 years in the IRIS trial cohort.
Authors: W N Kernan; C M Viscoli; L M Brass; R W Makuch; P M Sarrel; R S Roberts; M Gent; P Rothwell; R L Sacco; R C Liu; B Boden-Albala; R I Horwitz Journal: Stroke Date: 2000-02 Impact factor: 7.914
Authors: Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin Journal: N Engl J Med Date: 2006-08-10 Impact factor: 91.245
Authors: Katharine A Dobson Amato; Andrew Hyland; Robert Reed; Martin C Mahoney; James Marshall; Gary Giovino; Maansi Bansal-Travers; Heather M Ochs-Balcom; Michael A Zevon; K Michael Cummings; Chukwumere Nwogu; Anurag K Singh; Hongbin Chen; Graham W Warren; Mary Reid Journal: J Thorac Oncol Date: 2015-07 Impact factor: 15.609
Authors: Bruce Ovbiagele; Christopher J Weir; Jeffrey L Saver; Keith W Muir; Kennedy R Lees Journal: Cerebrovasc Dis Date: 2006-01-27 Impact factor: 2.762
Authors: I Kawachi; G A Colditz; M J Stampfer; W C Willett; J E Manson; B Rosner; F E Speizer; C H Hennekens Journal: JAMA Date: 1993-01-13 Impact factor: 56.272
Authors: Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder Journal: N Engl J Med Date: 2016-02-17 Impact factor: 91.245
Authors: Ashleigh Guillaumier; Sam McCrabb; Neil J Spratt; Michael Pollack; Amanda L Baker; Parker Magin; Alyna Turner; Christopher Oldmeadow; Clare Collins; Robin Callister; Chris Levi; Andrew Searles; Simon Deeming; Olivia Wynne; Alexandra M J Denham; Brigid Clancy; Billie Bonevski Journal: Trials Date: 2019-08-09 Impact factor: 2.279
Authors: Mateusz Lucki; Ewa Chlebuś; Agnieszka Wareńczak; Przemysław Lisiński Journal: Int J Environ Res Public Health Date: 2021-05-27 Impact factor: 3.390
Authors: Mateusz Lucki; Ewa Chlebuś; Agnieszka Wareńczak; Przemysław Lisiński Journal: Int J Environ Res Public Health Date: 2021-06-03 Impact factor: 3.390
Authors: Hypatia A Bolívar; Rebecca J Elliott; William Middleton; Jin H Yoon; Chizimuzo T C Okoli; Ilana Haliwa; Charles C Miller; Philip A Ades; Diann E Gaalema Journal: J Cardiopulm Rehabil Prev Date: 2021-01-01 Impact factor: 3.646